GlassScriptPhysician profile
William Donovan Delp
NPI 1225262579
$8,003.09
in general payments reported to CMS, 2019-2025
51 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $1,550 · 2021: $1,490 · 2022: $1,036 · 2023: $1,884 · 2024: $1,005 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,144 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,144.16 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $856.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $806.16 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $779.13 | 2020-2024 | Qulipta, Vraylar, Linzess |
| Lilly USA, LLC | $622.82 | 2019-2024 | Mounjaro, Emgality, Reyvow |
| Amgen INC. | $586.32 | 2019-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $440.22 | 2019-2025 | |
| Abbott Laboratories | $406.50 | 2021-2025 | Freestyle Libre 3, I-Stat |
| Glaxosmithkline, LLC. | $309.47 | 2020-2023 | Trelegy Ellipta, Arexvy |
| Supernus Pharmaceuticals, INC. | $255.68 | 2023 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.25 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $217.34 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $196.98 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $194.13 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $171.59 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.80 | 2019-2023 | Jardiance |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Delp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.